NICE consultation on kidney cancer drugs

The National Institute for Health and Clinical Excellence has recommended that bevacizumab, sorafenib, sunitinib and temsirolimus should not be treatment options for advanced or metastatic renal cell carcinoma.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here